Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 4,982 matching trials from the live ClinicalTrials.gov search.

Filters: San Diego, California Clear all

Conditions: Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
Interventions: ASQ-3, Bayley III, Neurologic exam; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 22 Months to 25 Months
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 24
States / cities: Montgomery, Alabama • Tucson, Arizona • La Mesa, California + 19 more

Conditions: Hemophilia A
Interventions: valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 15
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 12 more

Conditions: Breast Neoplasms, Breast Cancer, Metastasis
Interventions: CAL; Drug
Lead sponsor: Chugai Pharma USA; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 38
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Concord, California + 32 more

Conditions: Clinical High Risk, Psychosis, Remission, Conversion
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 12 Years to 30 Years
Enrollment: 2,617 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Leukemia, Myelocytic, Acute
Interventions: Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Busulfan and Cyclophosphamide, Cyclophosphamide and Total Body Irradiation; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 32
States / cities: Phoenix, Arizona • La Jolla, California • Gainesville, Florida + 27 more

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 27 more

Conditions: Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Interventions: Lumateperone; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 59
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Dasatinib and Rituximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Wet Age-related Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 65
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more

Conditions: Bacterial Infections
Interventions: Dalbavancin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Up to 28 Days
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Hematological Malignancies
Interventions: Magrolimab, Azacitidine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 26
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 20 more

Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 90
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 78 more

Conditions: Schizophrenia, Schizoaffective Disorder, Mood Disorder, Psychotic
Interventions: mobile Social Interaction Therapy by Exposure (mSITE); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: X-linked Hypophosphatemia, Hypophosphatemic Rickets
Interventions: No intervention; Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: Not listed
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Gastrointestinal Neoplasms, Pancreatic Cancer, Colorectal Cancer, GI Cancers, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC, GI Cancer
Interventions: Not listed
Lead sponsor: Canopy Cancer Collective, LLC; Network
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 10
States / cities: San Diego, California • Tampa, Florida • Baltimore, Maryland + 7 more

Conditions: HIV Infections
Interventions: In Vitro Diagnostic Device; Device
Lead sponsor: Chembio Diagnostic Systems, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 2,808 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: La Jolla, California • Fort Lauderdale, Florida • Baltimore, Maryland + 2 more

Conditions: Haemophilia A and B With and Without Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 19
States / cities: San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more

Conditions: Obesity
Interventions: Biometric-informed care, Control Arm: Standard Care; Behavioral
Lead sponsor: Jeff Reeves; Other
Eligibility: 18 Years to 64 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Diego, California

Conditions: Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
Interventions: OncoGel (Paclitaxel gel), cisplatin, 5-FU, radiation therapy, esophageal resection; Drug · Radiation · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo, Background PAH Therapy; Biological · Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more

Conditions: Posttraumatic Stress Disorder
Interventions: Computerized executive function training plus CPT (CEFT-CPT), Word game training plus CPT (WT-CPT); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Depressive Symptoms, Inflammation
Interventions: Pleasant Events Program (PEP), Information Support (IS); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 55 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer

AMP SCZ® Observational Study: PREDICT-DPACC

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Studying Fetal Breathing Patterns

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness

X-linked Hypophosphatemia Disease Monitoring Program

The Canopy Cancer Collective Clinical Registry Protocol

Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

Enhancement of PTSD Treatment With Computerized Executive Function Training

Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention